INGAPORE-DEVELOPED CANCER IMMUNOTHERAPY OFFERS NEW HOPE FOR LATE-STAGE CANCER PATIENTS PRL3-zumab demonstrates safety and clinical benefit in FDA-approved Phase II trial across multiple cancer types
READ MORE

INGAPORE-DEVELOPED CANCER IMMUNOTHERAPY OFFERS NEW HOPE FOR LATE-STAGE CANCER PATIENTS PRL3-zumab demonstrates safety and clinical benefit in FDA-approved Phase II trial across multiple cancer types

May 09, 2025
Intra-ImmuSG Focuses on Intracellular Targets for Cancer Immunotherapy
READ MORE

Intra-ImmuSG Focuses on Intracellular Targets for Cancer Immunotherapy

May 09, 2025
Unlocking New Therapeutic Pathways: PRL1 and PRL3 in Tumour Growth and Cancer Immunotherapy
READ MORE

Unlocking New Therapeutic Pathways: PRL1 and PRL3 in Tumour Growth and Cancer Immunotherapy

May 09, 2025
Targeted therapy sparks childhood cancer hope
READ MORE

Targeted therapy sparks childhood cancer hope

March 04, 2024

我们的首创新抗体抗癌药，为难治病人带来新希望。

联系我们
Top